Tumor Exosomes Reprogrammed by Low pH Are Efficient Targeting Vehicles for Smart Drug Delivery and Personalized Therapy against their Homologous Tumor
- PMID: 34026432
- PMCID: PMC8132050
- DOI: 10.1002/advs.202002787
Tumor Exosomes Reprogrammed by Low pH Are Efficient Targeting Vehicles for Smart Drug Delivery and Personalized Therapy against their Homologous Tumor
Abstract
As membrane-bound extracellular vesicles, exosomes have targeting ability for specific cell types, and the cellular environment strongly impacts their content and uptake efficiency. Inspired by these natural properties, the impacts of various cellular stress conditions on the uptake efficiency of tumor iterated exosomes are evaluated, and low-pH treatment caused increased uptake efficiency and retained cell-type specificity is found. Lipidomics analyses and molecular dynamics simulations reveal a glycerolipid self-aggregation-based mechanism for the enhanced homologous uptake. Furthermore, these low-pH reprogrammed exosomes are developed into a smart drug delivery platform, which is capable of specifically targeting tumor cells and selectively releasing diverse chemodrugs in response to the exosome rupture by the near-infrared irradiance-triggered burst of reactive oxygen species. This platform exerts safe and enhanced antitumor effects demonstrated by multiple model mice experiments. These results open a new avenue to reprogram exosomes for smart drug delivery and potentially personalized therapy against their homologous tumor.
Keywords: combination therapy; lipids rearrangement; low pH reprogramming; patient‐derived xenografts; tumor exosomes.
© 2021 The Authors. Advanced Science published by Wiley‐VCH GmbH.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer.Nanomedicine. 2018 Oct;14(7):1973-1985. doi: 10.1016/j.nano.2018.05.020. Epub 2018 Jun 20. Nanomedicine. 2018. PMID: 29935333
-
Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy.Theranostics. 2020 Jun 22;10(17):7889-7905. doi: 10.7150/thno.45028. eCollection 2020. Theranostics. 2020. PMID: 32685027 Free PMC article.
-
Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer.Cancer Lett. 2019 Sep 10;459:122-134. doi: 10.1016/j.canlet.2019.05.035. Epub 2019 Jun 5. Cancer Lett. 2019. PMID: 31173853
-
Tumor-derived nanovesicles promote lung distribution of the therapeutic nanovector through repression of Kupffer cell-mediated phagocytosis.Theranostics. 2019 Apr 13;9(9):2618-2636. doi: 10.7150/thno.32363. eCollection 2019. Theranostics. 2019. PMID: 31131057 Free PMC article.
-
A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.Biomaterials. 2014 Feb;35(7):2383-90. doi: 10.1016/j.biomaterials.2013.11.083. Epub 2013 Dec 15. Biomaterials. 2014. PMID: 24345736
Cited by
-
K. ZHENG ET AL.Gold-nanoparticle-based multistage drug delivery system for antitumor therapy.Drug Deliv. 2022 Dec;29(1):3186-3196. doi: 10.1080/10717544.2022.2128469. Drug Deliv. 2022. PMID: 36226475 Free PMC article.
-
Recent advances in redox-responsive nanoparticles for combined cancer therapy.Nanoscale Adv. 2022 Jul 28;4(17):3504-3516. doi: 10.1039/d2na00222a. eCollection 2022 Aug 23. Nanoscale Adv. 2022. PMID: 36134355 Free PMC article. Review.
-
Exosomes-based dual drug-loaded nanocarrier for targeted and multiple proliferative vitreoretinopathy therapy.Regen Biomater. 2024 Jun 29;11:rbae081. doi: 10.1093/rb/rbae081. eCollection 2024. Regen Biomater. 2024. PMID: 39040514 Free PMC article.
-
ECM stiffness affects cargo sorting into MSC-EVs to regulate their secretion and uptake behaviors.J Nanobiotechnology. 2024 Mar 21;22(1):124. doi: 10.1186/s12951-024-02411-w. J Nanobiotechnology. 2024. PMID: 38515095 Free PMC article.
-
The Progress and Evolving Trends in Nucleic-Acid-Based Therapies.Biomolecules. 2025 Mar 5;15(3):376. doi: 10.3390/biom15030376. Biomolecules. 2025. PMID: 40149911 Free PMC article. Review.
References
-
- Thery C., Zitvogel L., Amigorena S., Nat. Rev. Immunol. 2002, 2, 569. - PubMed
-
- Tkach M., Thery C., Cell 2016, 164, 1226. - PubMed
-
- Simons M., Raposo G., Curr. Opin. Cell Biol. 2009, 21, 575. - PubMed
-
- Syn N. L., Wang L., Chow E. K., Lim C. T., Goh B. C., Trends Biotechnol. 2017, 35, 665. - PubMed
-
- Farooqi A. A., Desai N. N., Qureshi M. Z., Librelotto D. R. N., Gasparri M. L., Bishayee A., Nabavi S. M., Curti V., Daglia M., Biotechnol. Adv. 2018, 36, 328. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials